Dr. Jordi Mestres


Jordi Mestres nomenat membre del Consell Científic de ChemBioFrance

Jordi Mestres, coordinador del grup de recerca en farmacologia de sistemes del GRIB, va ser oficialment nomenat el passat dia 10 de gener membre del Consell Científic de ChemBioFrance, una infraestructura nacional de recerca francesa dedicada al descobriment de petites molècules biològicament actives que reuneix quatre recursos i xarxes diferents: la col.lecció nacional de molècules (Chimiothèque Nationale), una xarxa de plataformes de cribratge, una plataforma de quimioinformàtica i una xarxa de plataformes per a l'avaluació del metabolisme i seguretat de molècules. Segons Jordi Mestres, "ChemBioFrance representa una aposta estratègica per integrar i gestionar tots els elements essencials en el descobriment de nous fàrmacs des d'una infraestructura pública. És un autèntic privilegi formar part del seu Consell Científic i poder contribuïr al desenvolupament d'aquesta iniciativa pionera a Europa".

More information


Thesis defense of William Blevins: "Evolutionary dynamics of transcriptional and translational regulation in yeast"

Next friday 17th of January at 10:00AMWilliam Blevins, member of the Evolutionary Genomics group of GRIB, will read his thesis: "Evolutionary dynamics of transcriptional and translational regulation in yeast".

The event will take place at the Ramon y Cajal room on the ground floor of PRBB. You are all invited to come. 

More information


Doctoral thesis of Tomasz Maciej Stępniewski : "Unraveling the complex signaling behavior of neurotransmitters and their receptors in the brain"

Next thursday 9th of January at 14:00, Tomek Stepniewski, member of  the GPCR Drug Discovery group of GRIB, will read his thesis: "Unraveling the complex signaling behavior of neurotransmitters and their receptors in the brain".

The event will take place at the Marie Curie room on the ground floor of PRBB. You are all invited to come. 

More information


El GRIB participa en la reunión de la red de bioinformática traslacional TransBioNet

El objetivo principal de TransBioNet es crear un foro de expertos donde los bioinformáticos que trabajan en entornos de investigación sanitaria compartan las mejores prácticas y experiencias de trabajo, tengan acceso temprano a los últimos desarrollos tecnológicos y directrices de organizaciones e iniciativas. El trabajo de la red se centra en tres pilares principales: estándares y evaluaciones comparativas, modelos de sostenibilidad y actividades de formación. 

La Red de Bioinformática Traslacional, TransBioNet, considerada de excelencia por el Ministerio de Ciencia, Innovación y Universidades, e impulsada y coordinada por el Instituto Nacional de Bioinformática, es una plataforma tecnológica del Instituto de Salud Carlos III. La red está integrada por más de 35 unidades de apoyo bioinformático a lo largo del país. Dada su naturaleza altamente colaborativa, TransBioNet está abierta a cualquier unidad de bioinformática vinculada a entornos sanitarios o servicios de apoyo de bioinformática en instituciones de investigación biomédica.

Ver noticia completa en la web del INB

More information


The Project CompBioMed 2 started on 1st October 2019 and will run for another 4 years.

The Computational Science Group of GRIB led by Gianni de Fabritiis is involved on this project and will have a central role regarding research on biomedical science, both with simulation methods and deep learning based applications. The group will also be working towards integrating results from modelling and simulation data with clinical and/or experimental data, supporting the combination of high-throughput data analytics with HPC based results, which will provide users a way to leverage the results produced by CompBioMed's research.

Read more about the project at

Read more about other projects of the Computational Science Group of GRIB

More information



Inside out: looking within our bodies improves drug design

Researchers from the IMIM Systems Pharmacology Research Group have analyzed 566 drugs and their endogenous ligands. The results help predict whether a drug may have undesired side effects.

The Systems Pharmacology group of GRIB has established for the first time a quantitative relationship between the affinities of the endogenous metabolites and of the drugs for the same proteins. Read the full interview to Jordi Mestres, head of this group, at the last edition of el·lipse magazine.

More information


Work from Mar Albà's group on the evolution of new genes featured in Nature News

Scientists long assumed that new genes appear when evolution tinkers with old ones. It turns out that natural selection is much more creative.  

Evolutionary genomicist Mar Albà, head of the Evolutionary Genomics Group of GRIB, had shown that the younger a gene is, evolutionarily speaking, the faster it tends to evolve. She speculated that this might be because the molecules encoded by younger genes are less polished and need more tuning, and that this could be a consequence of the genes having arisen de novo - they were not tied to a previous function as tightly as those that had evolved from older genes. Both Albà and Begun recall that it was challenging to publish their early work on the topic. "There was a lot of scepticism," says Albà. "It's amazing how things have changed."  

Read the article at Nature News 

More information

Double helix of DNA


Thesis lecture of Lara Nonell on November, 19th at 11:00: "New approaches in omics data modelling"

Next tuesday, 19th of November, at 11:00 AM, Lara Nonell, member of the Computational Human Biology Group of GRIB will defense her thesis "New approaches in omics data modelling" at the Ramón y Cajal room on the ground floor of PRBB. You are all invited to this event.

More information


Thesis lecture of José Jiménez on October 24th: "Machine learning in structural biology and chemoinformatics"

Next thursday, 24th of October at 10:00 AM, José Jiménez, member of the Computational Science Group of GRIB will defense his thesis "Machine learning in structural biology and chemoinformatics" at the Xipre room on the first floor of PRBB. You are all invited to this event.

More information


Our own bodies hold the key to designing safer drugs

The study was published in the prestigious journal Drug Discovery Today, which also dedicated the Editorial to it, and it has been reviewed by Nature Reviews Drug Discovery.

Based on a study of 566 drugs that interact with 129 different proteins, researchers from the Systems Pharmacology Group, in collaboration with researchers from the University of New Mexico, in the United States, realised that 71% of drugs have stronger affinities for their target proteins than those of the small internal molecules responsible for regulating their functions. Surprisingly, this is the first time that the affinities of endogenous ligands and drugs for the same proteins have been quantified.

"To date, no one had ever considered the idea that a drug's minimum interaction with its target protein should be similar to the affinity shown by the body's own small molecule. We have discovered that our own molecules, naturally optimised by evolution, provide the frame of reference necessary for efficiently designing more effective and safer drugs", explains Jordi Mestres, head of the Systems Pharmacology group.

More information

Site Information